In every controlled human trial run so far, NMN does one thing reliably: it increases blood NAD+ levels.¹ That quiet fact sits at the center of a story usually told with far more drama. David Sinclair, the Harvard geneticist who did more than anyone to make NMN a household word, points to a deep body of animal research and his own daily use. The honest summary: NMN’s human evidence is real but early — solid on NAD+, and far thinner on the sweeping age-reversal promises the internet now attaches to his name.
Key takeaways
- Sinclair popularized NMN, but much of the excitement rests on mouse studies and his personal regimen — not long human trials.
- Human trials consistently show NMN increases NAD+ and is well tolerated.* Signals on strength, walking, and metabolism are early and mixed.
- No long-term human trial has shown NMN slows aging or changes long-term health outcomes — a limitation Sinclair himself acknowledges.
- Judge NMN on its own human evidence and on product quality, not on headlines or any one person’s routine.
Who is David Sinclair, and why is he tied to NMN?
David Sinclair is a professor of genetics at Harvard Medical School and the author of the 2019 book Lifespan. He is best known for a framework he calls the information theory of aging: the idea that aging is driven largely by a loss of epigenetic information, the molecular instructions that tell cells how to behave. Over the past decade, his lab’s research and his very public advocacy turned NMN (β-nicotinamide mononucleotide) from an obscure molecule into one of the most-searched supplements in longevity. When people ask about “the David Sinclair NMN protocol,” that popularization is what they’re responding to.
Crediting his influence is fair. So is separating it from the evidence. A scientist can be genuinely important to a field and still be more optimistic in public than the human data yet justifies — and both things can be true of the NMN story at once.
What does David Sinclair actually claim about NMN?
Sinclair has said publicly, in interviews and on his own podcast, that he takes NMN daily — reportedly around a gram — typically alongside trans-resveratrol. His broader stated view is that NAD+ naturally declines with age, that this decline contributes to how cells age, and that increasing NAD+ is therefore a reasonable target worth studying. He has also acknowledged a real limitation: human trials to date have been short, so they can’t yet capture effects that might only show up over years.
Two honest caveats belong right next to those claims. First, a personal dose of about a gram a day is well above what most published human trials have tested, which cluster between 250 and 900 mg.¹² A public figure’s routine is not a dosing recommendation. Second, describing NAD+ as a “target worth studying” is a much more careful statement than the age-reversal headlines his name often appears under — and the gap between those two registers is exactly where hype tends to grow.
What do human NMN trials actually show?
Here the picture is genuinely encouraging in a narrow, specific way. In a 2023 randomized, double-blind trial of 80 healthy middle-aged adults, daily NMN increased blood NAD+ and was well tolerated across the doses studied, with several measures of physical performance peaking near 600 mg a day.¹ A separate randomized trial found 250 mg a day for 12 weeks was also well tolerated and increased NAD+ metabolism in healthy middle-aged adults.²
The single most consistent human finding is simple: NMN increases NAD+, and at the doses tested it has been well tolerated.* That is the sober core worth holding onto.
Beyond NAD+, the functional picture is genuinely mixed: some trials hint at modest effects on everyday measures like walking speed,³ while other analyses find little to no benefit for muscle strength or physical function in older adults — which is exactly why NMN’s human evidence is better called early than established. And the pattern of “increases NAD+, well tolerated” recurs across the wider precursor literature: a randomized trial of nicotinamide riboside (NR), a related NAD+ precursor, likewise increased NAD+ by roughly 60% and was well tolerated.⁴ None of this is a promise about how NMN will affect any one person — it measured biomarkers and short-term function, not aging itself.
Where the claims outrun the evidence: mice vs. people
The most striking results linked to Sinclair’s name come from mice — studies in which NAD+-boosting compounds appeared to rejuvenate blood vessels or restore exercise capacity in old animals. Those results are real and scientifically interesting. They are also, so far, mouse results. The history of aging research is full of compounds that dazzled in rodents and then did little in humans, which is why careful scientists treat the jump from mouse to person as a genuine unknown, not a formality.
The human trials that do exist tend to be short (often 8 to 12 weeks), small, and focused on surrogate markers like NAD+ rather than hard outcomes like lifespan or disease. Even the functional findings are mixed: some reviews of the human data have found little to no effect on measures such as muscle mass or strength in older adults. That is not a reason to dismiss NMN — it is a reason to describe it accurately as early-stage, and to be suspicious of anyone who describes it as settled.
The “age reversal” controversy — and why it matters here
It’s worth knowing the most-cited cautionary episode, because it shaped how many scientists now read big longevity claims. In 2024, Sinclair drew sharp criticism from fellow aging researchers over a bold age-reversal claim tied to a dog supplement from a company he co-founded. Prominent scientists publicly disputed the framing, and Sinclair stepped down as president of a longevity research academy amid a wave of member resignations.⁵
To be fair, that dispute was about age-reversal messaging, not specifically about NMN, and Sinclair has continued to lead serious research since — including work aimed at whole-body rejuvenation.⁶ But the takeaway is useful either way: separate a compelling communicator from the settled evidence, and judge each molecule on its own human data. That habit protects you far better than any single expert’s endorsement — or any single company’s marketing, ours included.
What this means if you’re considering NMN
Strip away the personalities and the story gets clearer and more useful.
- What we know: in human trials, NMN increases NAD+ and has been well tolerated at the doses studied (roughly 250–900 mg), with some early, mixed signals on physical function.*
- What we don’t know: whether NMN meaningfully slows aging or changes long-term health outcomes in humans. No long trial has shown that.
- What to do with that: if you try NMN, treat it as one small, optional part of a routine — not a shortcut — and don’t copy a celebrity gram-a-day dose by default. The published trials used less.
And because “legal and popular” is not the same as “verified,” product quality does more work than any famous name: a clearly stated dose, high purity, and a real third-party certificate of analysis matter more than whose routine a bottle is marketed against. If you’re curious how NMN fits into the bigger picture, our honest look at whether age reversal is realistic → and our overview of what the NMN research actually shows → both stay close to the evidence.
Where CELLSHE fits
We make NMN 500 → with the unglamorous parts done properly: a clearly stated dose of high-purity β-NMN, third-party tested, with a lot-matched certificate of analysis available on request. It’s designed to support cellular energy production* as one optional part of a consistent daily routine — not a shortcut, and not something any label should oversell. We don’t claim celebrity endorsements, and we don’t promise age reversal; we’d rather you judge NMN on its evidence. COA requests are always welcome at hello@cellshe.com.
Not sure where to begin? Our free Cellular Age Check takes about 2 minutes: take the free Cellular Age Check →. To see how NMN sits alongside NAD+ and resveratrol, start with our plain-English guide to NMN supplements →.
Frequently asked questions
Does David Sinclair take NMN?
Yes. Sinclair has said publicly, in interviews and on his podcast, that he takes NMN daily, typically alongside trans-resveratrol. He has framed it as part of a personal longevity routine rather than a proven treatment, and has been open that human trials remain early.
How much NMN does David Sinclair take?
He has described taking roughly a gram (about 1,000 mg) a day. That is well above the doses used in most published human trials, which have generally tested between 250 and 900 mg. A public figure’s personal dose is not a dosing guideline, and more is not automatically better.
Does NMN actually slow aging like the headlines suggest?
No — not in humans, on the current evidence. Human trials show NMN increases NAD+ and is well tolerated, but none has shown it slows human aging or changes long-term health outcomes. Much of the age-reversal excitement comes from mouse studies, which don’t reliably translate to people.
Is NMN backed by human studies?
Yes, but early ones. Randomized trials show NMN increases blood NAD+ and is well tolerated at the doses studied, with some early and mixed signals on physical function.* The research is genuine but short-term and focused on biomarkers, not long-term health outcomes.
Should I take NMN just because David Sinclair does?
That’s not a strong reason on its own. Base the decision on the human evidence and on product quality — purity, a stated dose, and third-party testing — and talk with your clinician first if you are pregnant, nursing, taking medication, or managing a health condition.
References
- Yi L, Maier AB, et al. (2023). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. PMID: 36482258. pubmed.ncbi.nlm.nih.gov/36482258
- Katayoshi T, et al. (2023). Nicotinamide mononucleotide metabolism after long-term supplementation: a randomized, double-blind, placebo-controlled study. Scientific Reports. PMID: 36797393. pubmed.ncbi.nlm.nih.gov/36797393
- Morifuji M, Higashi S, Ebihara S, Nagata M. (2024). Ingestion of β-nicotinamide mononucleotide increased blood NAD+ levels, maintained walking speed, and improved sleep quality in older adults in a double-blind, randomized, placebo-controlled study. GeroScience. PMID: 38789831. pubmed.ncbi.nlm.nih.gov/38789831
- Martens CR, et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. PMID: 29599478. pubmed.ncbi.nlm.nih.gov/29599478
- Molteni M. (2024). Harvard’s David Sinclair gets blowback over aging-reversal claim. STAT. statnews.com
- Regalado A. (2026). David Sinclair plans to test whole-body rejuvenation drugs in the XPrize competition. MIT Technology Review. technologyreview.com
